Our Technology

Driven by technology, supported by data, focused on insight.

Our approaches live at the nexus of analytical technologies, computational learning, and population-scale clinical studies.

There is a fundamental mismatch between disease diagnosis and treatment that has given rise to the inefficiencies still seen in drug development today. Aligning biological targets, disease states, and therapies requires discovery of biomarkers that identify patients most likely to benefit from specific treatments. That is where Sapient’s Biomarker Discovery Engine comes in.

Find biomarkers that matter most, at unmatched speed

Leverage our proprietary patient database to derive accurate insights into the meaning and specificity of identified biomarkers.

Accelerate pipeline development at any phase

Guide development of new or stalled drugs while reducing trial inefficiency, with rapid translation from discovery to CLIA assays.

Engage Us Today

Sapient’s Core Technology

Take a closer look
at our platform.

Our methods reduce the complexity of biomarker discovery while enabling identification of biomarkers at an entirely new scale and level of fidelity.

Analytical Technologies

Sapient’s next-generation rapid liquid chromatography-mass spectrometry (rLC-MS) infrastructure and automated workflows scale the speed and capacity of current analytical technologies, assaying tens of thousands of molecules per biosample in less than 1 minute. Using untargeted molecular profiling, these systems enable discovery of uncharacterized compounds.

Computational Learning

Applying proprietary statistical and machine learning tools to the generated data, Sapient enables identification of key molecules that provide actionable insights for your drug development program, such as biomarkers of target engagement, biological processes, disease progression, or adverse response.

Human Biology Database

Sapient’s longitudinal human chemical databases are the most extensive generated to date, spanning hundreds of thousands of human biosamples and over 20 million patient-years of phenotype data. We reference these to derive insight into the specificity of biomarkers elucidated in a study.

Collectively, these technologies enable Sapient to:

  • Identify key biological mechanisms of disease

  • Confirm pharmacological engagement of key targets

  • Provide early insight into potential drug safety risks

  • Uncover dosing and timing of drug targets

  • Align patients, disease states, and therapies

A Culture of Quality

Consistency, collaboration, and radical transparency.

We pride ourselves on upholding the most rigorous culture of quality. Our laboratory adheres to stringent regulatory standards in practice, including: